Revenue increased 41.8% year-on-year to ₹4,197 crore from ₹2,959 crore. EBITDA rose 40.7% to ₹1,356 crore from ₹964 crore, while EBITDA margin stood at 32% compared with 33% in the year-ago period.
Torrent Pharmaceuticals reported India business revenues of ₹2,215 crore, up 43%, with base business growth of 15%, outpacing IPM growth of 10% as per AIOCD PharmaTrac data.
Also Read: Torrent Pharma Q2 Results: Profit up 30% YoY; US, India growth lift revenue 14%
For FY26, India revenues stood at ₹7,645 crore, up 20%, with the company noting that its base business remains among the fastest growing in the top 10 pharma firms. The Gx Semaglutide launch also saw a strong start, securing 38% market share (oral and injectable combined) as per April 26 PharmaTrac data.
In Brazil, revenues rose 30% to ₹455 crore, while constant currency revenues increased 11% to R$ 259 million. As per IQVIA, Torrent grew 17% versus market growth of 6%, supported by the performance of top brands and recent launches. The company has 58 products under ANVISA review. For FY26, Brazil revenues were ₹1,362 crore, up 24%, with constant currency revenue at R$ 823 million, up 12%.
Also Read: Torrent Pharma’s Gujarat oncology plant inspection by USFDA concludes with zero observations
In the United States, revenues increased 31% to ₹396 crore, with base business revenue rising 16% and constant currency revenue of $38 million, up 9%. For FY26, US revenues stood at ₹1,363 crore, up 24%, while base business grew 20%, supported by recent launches, with constant currency revenue at $149 million, up 14%.
In Germany, revenues rose 16% to ₹333 crore, while constant currency revenues declined 1% to €31 million due to supply disruptions at a third-party supplier. For FY26, Germany revenues stood at ₹1,249 crore, up 10%, while constant currency revenue fell 3% to €122 million.
The company has recommended obtaining enabling approval from shareholders to raise up to ₹5,000 crore through issuance of equity shares, including convertible bonds or debentures, via Qualified Institutional Placement (QIP) and/or other permitted modes at its upcoming Annual General Meeting.
Also Read: Torrent Pharma Q3 net profit surges 26% on strong revenue growth, declares ₹29 dividend
It has also recommended a final dividend of ₹9 per equity share of face value ₹5, equivalent to 180%, for FY26. If approved by shareholders, the dividend is expected to be paid or dispatched on or around June 25, 2026.
Earlier, Torrent Pharmaceuticals had paid an interim dividend of ₹29 per equity share, equivalent to 580%, during the last quarter.
Shares of Torrent Pharmaceuticals Ltd ended at ₹4,494.00, up by ₹23.15, or 0.52%, on the BSE.
